Michel Ducreux

Also affiliated with Université Paris-Saclay, Institut Gustave Roussy

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma”.

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

New England Journal of Medicine(2020)10.1056/nejmoa1915745

N/A

1.3DataRank · unranked

7029 citations

Shukui Qin, Masafumi Ikeda, Peter R. Galle, Michel Ducreux, Tae-You Kim +19 more

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

New England Journal of Medicine(2011)10.1056/nejmoa1011923

N/A

1.3DataRank · unranked

6381 citations

Françoise Desseigne, Marc Ychou, Olivier Bouché, Rosine Guimbaud, Yves Bécouarn +21 more

Phase Ib/II Study of the Efficacy and Safety of Binimetinib (MEK162) Plus Panitumumab for Mutant or Wild-Type RAS Metastatic Colorectal Cancer

The Oncologist(2023)10.1093/oncolo/oyad210

N/A

0.250DataRank · unranked

3 citations

Rona Yaeger, Jean‐Pierre Delord, Josep Tabernero, Lillian L. Siu, Michel Ducreux +9 more